Cargando…
Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
Postprandial glucose excursions are postulated to increase the risk for diabetes complications via the production of advanced glycation end products (AGEs). The soluble receptor of AGEs (sRAGE) likely acts as a decoy receptor, mopping up AGEs, diminishing their capacity for pro-inflammatory and pro-...
Autores principales: | Fotheringham, Amelia K., Bagger, Jonatan I., Borg, Danielle J., McCarthy, Domenica A., Holst, Jens J., Vilsbøll, Tina, Knop, Filip K., Forbes, Josephine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598639/ https://www.ncbi.nlm.nih.gov/pubmed/32987824 http://dx.doi.org/10.3390/nu12102928 |
Ejemplares similares
-
A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022) -
Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis
por: Wu, Rui, et al.
Publicado: (2020) -
Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013) -
Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD
por: Gopal, Poornima, et al.
Publicado: (2014) -
Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?
por: Eleazu, Chinedum, et al.
Publicado: (2019)